A human natural antibody to adenocarcinoma that inhibits tumour cell migration

Koda, Keiji; Nakajima, Noboru; Saito, Norihiko; Yasutomi, Jun; McKnight, Michael E.; Glassy, Mark C.

doi:10.1038/bjc.1998.677

Cited by 11 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Koda et al [18] the B-lymphocyte eventually becoming SK-1 was one hybridoma of 1036 analysed. This would suggest that the human anticancer humoral immune response is not as prevalent as thought, at least with the patient from whom SK-1 came.…”

Section: Glassy Yasutomi and Koda 997mentioning

confidence: 98%

“…Prior studies [7,14,18,19,24,31] have demonstrated the clinical utility of obtaining antibody-secreting B-cells from regional draining lymph nodes and their applications in cancer diagnosis and therapy. The principles learned should be applicable to lung cancer.…”

Section: Experimental Modelmentioning

confidence: 99%

“…Some practical examples which demonstrate the feasibility of this drug discovery approach are SK-1 [7,[15][16][17][18] and AE6F4 [19,20], both of which are considered important tumour antibodies. Therefore, now that the existence of a human antibody response to real tumour antigens has been established, then the question is, how many of these tumour antigens exist?…”

Section: Drug Discoverymentioning

confidence: 99%

“…One will consist of known antigens such as the Ep-CAM antigen [23], the antigen to AE6F4 [20], or the ganglioside GD3 [24,25], and the other class will consist of novel antigens such as AgSK1 [18] or AgTB94 [21,22], which have not been previously described. This could be significant, especially in light of the fact that the human immune response recognises allotypic antigens immunologically blind to other species.…”

Section: Glassy Yasutomi and Koda 997mentioning

confidence: 99%

“…Practical upper and lower limits can be placed on this. We know from studies to date that a few human immune response-defined tumour antigens have already been identified [3,8,[18][19][20][21][22].…”

Section: Drug Discoverymentioning

confidence: 99%

See 4 more Smart Citations

Lessons learned about the therapeutic potential of the natural human immune response to lung cancer

Glassy¹,

Yasutomi²,

Koda³

1999

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths; patients with this disease often develop antibodies to their own tumour antigens. TB94 is one such human antibody, and was obtained from the natural immune response from a patient with lung cancer. The data generated so far on TB94 suggest that this human antibody may have clinical applications in the diagnosis and treatment of lung cancer. Since humans make antibodies to tumour antigens, the intelligence of the human immune response can be exploited for the discovery of potential novel antigens. These novel antigens can then be developed for vaccine applications. Creating effective strategies to analyse systematically the natural human immune response to tumour antigens will open up new areas of immunotherapy for the control and eradication of disease.

show abstract

Section: Glassy Yasutomi and Koda 997mentioning

confidence: 98%

Section: Experimental Modelmentioning

confidence: 99%

Section: Drug Discoverymentioning

confidence: 99%

Section: Glassy Yasutomi and Koda 997mentioning

confidence: 99%

Section: Drug Discoverymentioning

confidence: 99%

See 3 more Smart Citations

Lessons learned about the therapeutic potential of the natural human immune response to lung cancer

Glassy¹,

Yasutomi²,

Koda³

1999

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

Technical and Ethical Limitations in Making Human Monoclonal Antibodies (An Overview)

Glassy¹,

Gupta

2013

Methods in Molecular Biology

View full text Add to dashboard Cite

In the broadest sense there are no longer any technical limitations to making human mAbs. Biological issues involving the type and nature of either a synthetic or a natural antibody, advantages of various B cell immunological compartments, and various assays needed to qualitate and quantitate mAbs have essentially been solved. If the target antigen is known then procedures to optimize antibody development can be readily planned out and implemented. When the antigen or target is unknown and specificity is the driving force in generating a human mAb then considerations about the nature and location of the B cell making the sought after antibody become important. And, therefore, the person the B cell is obtained from can be an ethical challenge and a limitation. For the sources of B cells special considerations must be taken to insure the anonymity and privacy of the patient. In many cases informed consent is adequate for antibody development as well as using discarded tissues. After the antibody has been generated then manufacturing technical issues become important that greatly depend upon the amounts of mAb required. For kilogram quantities then special considerations for manufacturing that include FDA guidelines will be necessary.

show abstract

Monoclonal antibody therapy

Dillman

2009

Principles of Cancer Biotherapy

View full text Add to dashboard Cite

A human natural antibody to adenocarcinoma that inhibits tumour cell migration

Cited by 11 publications

References 28 publications

Lessons learned about the therapeutic potential of the natural human immune response to lung cancer

Lessons learned about the therapeutic potential of the natural human immune response to lung cancer

Technical and Ethical Limitations in Making Human Monoclonal Antibodies (An Overview)

Monoclonal antibody therapy

Contact Info

Product

Resources

About